# US 2017/0281649 A1 · Compounds and therapeutic uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281649 A1
- Document ID: US20170281649A1
- Status: Published application
- Kind: A1
- Application number: 15/069,769
- Filed: 2016-03-14
- Published: 2017-10-05
- Earliest claimed: 2015-03-13
- Assignees: Unity Biotechnology, Inc.
- Applicants: Unity Biotechnology, Inc.
- Inventors: Nathaniel David
- Web page: https://patentgrep.com/patent/US20170281649A1

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/11: Aldehydes
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/365: Lactones
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/426: 1,3-Thiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/433: Thidiazoles
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4741: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.

## Claims

### Claim 1

A method for treating a senescence-associated condition comprising administering to a subject in need thereof a compound selected from:
or a salt of anyone thereof, wherein the senescence-associated condition is not cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound or salt is administered at an amount less than a dose effective for cancer treatment.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound or salt is administered in at least two treatment cycles, wherein each treatment cycle independently comprises a treatment course of from 1 day to 3 months followed by a non-treatment interval of at least 2 weeks.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound or salt is administered in a single dose.

### Claim 5 (depends on 3)

The method of claim 3, wherein each treatment cycle is no longer than one month.

### Claim 6 (depends on 5)

The method of claim 5, wherein each treatment cycle is no longer than 5 days.

### Claim 7 (depends on 3)

The method of claim 3, wherein the compound or salt is administered every 2nd or every 3rd day of each treatment cycle.

### Claim 8 (depends on 3)

The method of claim 3, wherein the treatment cycle is one day, two days, three days, or four days.

### Claim 9 (depends on 3)

The method of any claim 3, wherein the compound or salt is administered daily during each treatment cycle.

### Claim 10 (depends on 3)

The method of claim 3, wherein the non-treatment interval is at least two weeks.

### Claim 11 (depends on 3)

The method of claim 3, wherein the treatment cycle is one day and the non-treatment interval is between 0.5-12 months.

### Claim at position 12

-19. (canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the senescence-associated condition is atherosclerosis; osteoarthritis; glaucoma; pulmonary fibrosis; hypertension, or chronic obstructive pulmonary disease.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the compound or salt is combined with at least one pharmaceutically acceptable excipient to formulate a pharmaceutically acceptable composition to provide timed-release of the compound or salt.

### Claim 23 (depends on 1)

The method of claim 1, wherein the compound or salt is administered as a bolus infusion.

### Claim 24 (depends on 20)

The method of claim 20, wherein the senescence-associated condition is osteoarthritis and the compound or salt is administered directly into the osteoarthritic joint.

### Claim 25 (depends on 24)

The method of claim 24, wherein the compound or salt is administered intra-articularly to the osteoarthritic joint.

### Claim 26 (depends on 1)

The method of claim 1, wherein the compound or salt is administered topically, transdermally, or intradermally.

### Claim at position 20

-33. (canceled)

### Claim 34 (depends on 1)

The method of claim 1, wherein the method kills senescent cells and senescent cells are selected from senescent preadipocytes, senescent endothelial cells, senescent fibroblasts, senescent neurons, senescent epithelial cells, senescent mesenchymal cells, senescent smooth muscle cells, senescent macrophages, senescent chondrocytes or combinations thereof.

### Claim 35 (depends on 34)

The method of claim 34, wherein the compound or salt kills at least 20% of the senescent cells and kills no more than 5% of non-senescent cells in an organ or tissue comprising the senescent cells associated with the senescence-associated condition.

### Claim 36 (depends on 35)

The method of claim 35, wherein the compound or salt kills at least 25% of the senescent cells in an organ or tissue comprising the senescent cells associated with the senescence-associated condition.
